Skip to main content

AB Sciex, GeneBio Ink Co-marketing Deal

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – AB Sciex and Geneva Bioinformatics (GeneBio) today said that they will co-market products aimed at improving the ability of scientists to conduct rapid screening of large sets of molecules.

The firms will co-market AB Sciex's mass spectrometers and software applications with GeneBio's SmileMS software for advanced library searching capabilities. They said the GeneBio software complements AB Sciex's Analyst and Cliquid software and is fully compatible with AB Sciex's LC/MS/MS libraries for forensic, pesticide, veterinary, and antibiotics analysis.

The combined technologies will "create new opportunities to improve results in clinical and forensic toxicology, among other fields that can take advantage of these capabilities," Joe Anacleto, VP and GM of the applied markets and clinical research business for AB Sciex, said in a statement.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.